Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania 15232

6 studies enrolling now · 23 studies all time

What they study most

Acquired Hemophilia A, Adeno-Associated Virus (AAV), Bleeding, Bleeding Disorder, Bleeding Disorders, Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Connective Tissue Disorder, Factor IX Deficiency, Factor VIII (FVIII), Factor VIII (FVIII) Deficiency

Studies at this site

• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Recruiting now
• A Study Assessing HMB-002 in Participants With Von Willebrand Disease — Recruiting now
• Study of Individuals Affected With Hypoplasminogenemia — Recruiting now
• A Study of Bleeding and Treatment in Participants With Von Willebrand Disease — Recruiting now
• Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders — Recruiting now
• ATHN 9: Severe VWD Natural History Study — Completed
• A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) — Enrolling by invitation
• Emicizumab in Patients With Acquired Hemophilia A — Running, not enrolling
• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B — Stopped early
• A Gene Transfer Study for Hemophilia A — Completed
• Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A — Running, not enrolling
• Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors — Completed
• Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg — Completed
• Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry — Stopped early
• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 — Completed
• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery — Completed
• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) — Completed
• Hemophilia Inhibitor Previously Untreated Patient Study — Completed
• Weight-based Dosing in Hemophilia A — Stopped early
• LTFU for Gene Transfer Subjects With Hemophilia B — Completed
• Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform — Withdrawn before enrolling
• Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A — Stopped early
• Rituximab to Treat Severe Hemophilia A — Completed